Boston Scientific Corporation (BSX) News
Filter BSX News Items
BSX News Results
|Event/Time||Symbol||Company||News Detail||Start||End||Change||POWR Rating|
|Loading, please wait...|
Latest BSX News From Around the Web
Below are the latest news stories about Boston Scientific Corp that investors may wish to consider to help them evaluate BSX as an investment opportunity.
Boston Scientific (NYSE: BSX) announced the U.S. launch of the DIRECTSENSE™ Technology, a tool for monitoring the effect of radiofrequency (RF) energy delivery during cardiac ablation procedures. Available on the RHYTHMIA HDx™ Mapping System, the DIRECTSENSE Technology, which received U.S. Food and Drug Administration approval in April, is the only tool to monitor changes in local impedance – electrical resistance – around the tip of the INTELLANAV™ MiFi Open-Irrigated (OI) ablation catheter, offering physicians an additional measurement of therapy effect during an ablation.
How leaders should address race with their employees, the Warren Buffett of tech, and top healthcare startups
Hello, New York. Atlanta. Los Angeles. Denver. Dallas. Detroit. Washington, DC. Seattle. Miami. Chicago. Thousands marched in cities across the US last night, with many of the protests turning violent. The protests first broke out in Minneapolis after a black man, George Floyd, was killed after a white police officer knelt on his neck for nearly nine minutes during an arrest, and as Floyd said he couldn't breathe. The arrest was caught on video, and the Minneapolis police officer who knelt on George Floyd's neck has since been charged with third-degree murder and manslaughter . As Tati Bellamy Walker and Shana Lebowitz report, a memo from medical-device-manufacturing firm Boston Scientific on the killing of George Floyd is a case study in how leaders should address the events in Minneso...
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Visa and Cigna make the list Continue reading...
Boston Scientific Completes Approximately $2.0 Billion Aggregate Offerings of Common Stock and Mandatory Convertible Preferred Stock
MARLBOROUGH, Mass. , May 27, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) completed the concurrent offerings of (i) 29,382,500 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 3,832,500 additional shares of common stock, at a public offering price of $34.25 per share and (ii) 10,062,500 shares of its 5.50% Mandatory Convertible Preferred Stock, Series A ("Mandatory Convertible Preferred Stock"), which includes the exercise in full by the underwriters of their overallotment option to purchase up to 1,312,500 additional shares of Mandatory Convertible Preferred Stock, at a price to the public and liquidation preference of $100.00 per share (collectively, the "offerings"). The net proceeds from the Comm...
MARLBOROUGH, Mass., May 26, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Jefferies 2020 Virtual Healthcare Conference on June 2. Joe Fitzgerald, executive vice president and president, Rhythm Management; Kenneth Stein, M.D., senior vice…
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
Boston Scientific shares fall after the medical-device maker said it would sell $1.5 billion of common and preferred stock.
China's Medical Device Market Analysis and Forecasts (2020-2024), Featuring Boston Scientific Corporation, Medtronic and MicroPort Scientific
DUBLIN, May 21, 2020 /PRNewswire/ -- The "China Medical Device Market: Size, Trends and Forecasts (2020-2024)" report has been added to ResearchAndMarkets.com's offering. This report provides an in-depth analysis of the medical device market in China including a detailed description of…
MARLBOROUGH, Mass. , May 21, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) announced the pricing of concurrent offerings of 25,550,000 shares of its common stock ("Common Stock") at a price to the public of $34.25 per share and 8,750,000 shares of its 5.50% Mandatory Convertible Preferred Stock, Series A ("Mandatory Convertible Preferred Stock") at a price to the public and liquidation preference of $100.00 per share. The underwriters have separate 30-day options to purchase up to an additional 3,832,500 shares of Common Stock and up to an additional 1,312,500 shares of Mandatory Convertible Preferred Stock. The offerings are expected to close on May 27, 2020 , subject to customary closing conditions. The net proceeds from the Common Stock offering and the Mandatory Co...